Cargando…
Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL
BACKGROUND: The clinical application of TRAIL receptor agonists as a novel cancer therapy has been tempered by heterogeneity in tumour responses. This is illustrated in breast cancer, where TRAIL is cytotoxic in cell lines of mesenchymal origin but refractory in lines with an epithelial-like phenoty...
Autores principales: | French, Rhiannon, Hayward, Olivia, Jones, Samuel, Yang, William, Clarkson, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678708/ https://www.ncbi.nlm.nih.gov/pubmed/26667821 http://dx.doi.org/10.1186/s12943-015-0478-y |
Ejemplares similares
-
FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP
por: Tsuchiya, Yuichi, et al.
Publicado: (2015) -
Computational modelling of LY303511 and TRAIL-induced apoptosis suggests
dynamic regulation of cFLIP
por: Shi, Yuan, et al.
Publicado: (2013) -
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
por: Lemke, J, et al.
Publicado: (2014) -
Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation
por: Henrich, C J, et al.
Publicado: (2015) -
Induction of Breast Cancer Cell Apoptosis by TRAIL and Smac Mimetics: Involvement of RIP1 and cFLIP
por: Holmgren, Christian, et al.
Publicado: (2022)